A list of encapsulated nucleosidic analogs for cancer treatment.
| Name | Active molecule | Statusa | Nanocarrier | Targeted cancer | Encapsulation efficiency | |
|---|---|---|---|---|---|---|
| Vyxeos (cpx-351) | • Cytarabine | • FDA approved (2017) | • Liposome | • Acute myeloid leukemia | • 5% | 108 and 109 |
| • Daunorubicin | • EMA approved (2018) | |||||
| • Clinical trial phase IV | ||||||
| DepoCyt™ | • Cytarabine | • FDA approved (1999) | • Liposome | • Lymphomatous meningitis | • 86.30% | 110–112 |
| • EMA approved (2008) | ||||||
| • Withdrawn | ||||||
| Gemcitabine-loaded liposomes | • Gemcitabine | • Preclinical | • Liposome | • Anaplastic thyroid carcinoma | • 90% | 156 |
| GemC16-loaded 2N-LPs | • Gemcitabine | • Preclinical | • Liposome | • Pancreatic cancer | • 97.3% | 157 |
| • Loading capacity (8.9%) | ||||||
| Decitabine LNCs | • Decitabine | • Preclinical | • Lipid nanocapsules | • Acute myeloid leukemia | • 88% | 158 |
a
Trial status was verified by the NIH – U.S. National Library of Medicine clinical trials database (http://www.clinicaltrials.gov). Approval status was verified by the European Medicines Agency (http://www.ema.europa.eu) and the US Food and Drug Administration (http://www.fda.gov).